Expression of high Km 5′-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia

Blood

Volumn 98, Issue 6, 2001, Pages 1922-1926

  Galmarini, Carlos M ^a,b,c,d   Graham, Kathryn ^a,b,c,d   Thomas, Xavier ^a,b,c,d   Calvo, Fabien ^a,b,c,d   Rousselot, Philippe ^a,b,c,d   Jafaari, Assia El ^a,b,c,d   Cros, Emeline ^a,b,c,d   Mackey, John R ^a,b,c,d   Dumontet, Charles ^a,b,c,d  

^a INSERM   (France)

^b CROSS CANCER INSTITUTE   (Canada)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; CYTARABINE; CYTARABINE TRIPHOSPHATE; MESSENGER RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0035885953     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.6.1922     Document Type: Article

References (45)

1. Hiddemann W. Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens. Ann Hematol. 1991;62:119-128.
2. Rowe JM. What is the best induction regimen for acute myelogenous leukemia? Leukemia. 1998;12(suppl 1):S16-19.
3. Burk M, Heyll A, Arning M, Volmer M, Fartash K, Schneider W. Pharmacokinetics of high-dose cytarabine and its deamination product-a reappraisal. Leuk Lymphoma. 1997;27:321-327.
4. Del Poeta G, Stasi R, Aronica G, et al. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood. 1996;87:1997-2004.
5. List AF, Spier CS, Grogan TM, et al. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood. 1996;87:2464-2469.
6. Michieli M, Damiani D, Ermacora A, et al. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications. Br J Haematol. 1999;104:328-335.
7. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997;89:3323-3329.
8. Schuurhuis GJ, Broxterman HJ, Ossenkoppele GJ, et al. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia. Clin Cancer Res. 1995;1:81-93.
9. Mackey JR, Baldwin SA, Young JD, Cass CE. The role of nucleoside transport in anticancer drug resistance. Drug Resistance Updates. 1998;1:310-324.
10. Coleman CN, Stoller RG, Drake JC, Chabner BA. Deoxycytidine kinase: properties of the enzyme from human leukemic granulocytes. Blood, 1975;46:791-803.
11. Liliemark JO, Plunkett W, Dixon DO. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5′-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1985;45:5952-5957.
12. Plunkett W, Liliemark JO, Estey E, Keating MJ. Saturation of ara-CTP accumulation during highdose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C. Semin Oncol. 1987;14:159-166.
13. Kantarjian HM, Estey EH, Plunkett W, et al. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med. 1986;81:387-394.
14. Kufe D, Spriggs D, Egan EM, Munroe D. Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells. Blood. 1984;64:54-58.
15. Rustum YM, Raymakers RA. 1-Beta-arabinofuranosylcytosine in therapy of leukemia: preclinical and clinical overview. Pharmacol Ther. 1992;56:307-321.
16. Laliberte J, Momparler RL. Human cytidine deaminase: purification of enzyme, cloning, and expression of its complementary DNA. Cancer Res. 1994;54:5401-5407.
17. Madrid-Marina V, Lestan B, Nowak PJ, Fox IH, Spychala J. Altered properties of human T-lymphoblast soluble low Km 5′-nucleotidase: comparison with B-lymphoblast enzyme. Leuk Res. 1993;17:231-240.
18. Rampazzo C, Gazziola C, Ferraro P, et al. Human high-Km 5′-nucleotidase effects of overexpression of the cloned cDNA in cultured human cells. Eur J Biochem. 1999;261:689-697.
19. Jamieson GP, Snook MB, Wiley JS. Saturation of intracellular cytosine arabinoside triphosphate accumulation in human leukemic blast cells. Leuk Res. 1990;14:475-479.
20. Kufe DW, Major PP, Egan EM, Beardsley GP. Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem. 1980;255:8997-9000.
21. Major PP, Egan EM, Herrick DJ, Kufe DW. Effect of ARA-C incorporation on deoxyribonucleic acid synthesis in cells. Biochem Pharmacol. 1982;31:2937-2940.
22. Gati WP, Paterson AR, Larratt LM, Turner AR, Belch AR. Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein. Blood. 1997;90:346-353.
23. Bhalla K, Nayak R, Grant S. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1984;44:5029-5037.
24. Dumontet C, Fabianowska-Majewska K, Mantincic D, et al. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol. 1999;106:78-85.
25. Schroder JK, Kirch C, Flasshove M, et al. Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro. Leukemia. 1996;10:1919-1924.
26. Resta R, Yamashita Y, Thompson LF. Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol Rev. 1998;161:95-109.
27. Zimmermann H. 5′-Nucleotidase: molecular structure and functional aspects. Biochem J. 1992;285:345-365.
28. Boyle JM, Hey Y, Guerts van Kessel A, Fox M. Assignment of ecto-5′-nucleotidase to human chromosome 6. Hum Genet. 1988;81:88-92.
29. Misumi Y, Ogata S, Ohkubo K, Hirose S, Ikehara Y. Primary structure of human placental 5′-nucleotidase and identification of the glycolipid anchor in the mature form. Eur J Biochem. 1990;191:563-569.
30. Richardson PJ, Brown SJ, Bailyes EM, Luzio JP. Ectoenzymes control adenosine modulation of immunoisolated cholinergic synapses. Nature. 1987;327:232-234.
31. Pieters R, Thompson LF, Broekema GJ, et al. Expression of 5′-nucleotidase (CD73) related to other differentiation antigens in leukemias of B-cell lineage. Blood. 1991;78:488-492.
32. Itoh R, Echizen H, Higuchi M, Oka J, Yamada K. A comparative study on tissue distribution and metabolic adaptation of IMP-GMP 5′-nucleotidase. Comp Biochem Physiol B. 1992;103:153- 159.
33. Spychala J, Madrid-Marina V, Fox IH. Evidence for "low Km" and "high Km" soluble 5′-nucleotidases in human tissues and rat liver. Adv Exp Med Biol. 1989;253B:129-134.
34. Oka J, Matsumoto A, Hosokawa Y, Inoue S. Molecular cloning of human cytosolic purine 5′-nucleotidase. Biochem Biophys Res Commun. 1994;205:917-922.
35. Allegrini S, Pesi R, Tozzi MG, Fiol CJ, Johnson RB, Eriksson S. Bovine cytosolic IMP/GMP-specific 5′-nucleotidase: cloning and expression of active enzyme in Escherichia coli. Biochem J. 1997;328:483-487.
36. Spychala J, Madrid-Marina V, Fox IH. High Km soluble 5′-nucleotidase from human placenta. Properties and allosteric regulation by IMP and ATP. J Biol Chem. 1988;263:18759-18765.
37. Paglia DE, Valentine WN, Brockway RA. Identification of thymidine nucleotidase and deoxyribonucleotidase activities among normal isozymes of 5′-nucleotidase in human erythrocytes. Proc Natl Acad Sci U S A. 1984;81:588-592.
38. Rampazzo C, Johansson M, Gallinaro L, et al. Mammalian 5′(3′)-deoxyribonucleotidase, cDNA cloning, and overexpression of the enzyme in Escherichia coli and mammalian cells. J Biol Chem. 2000;275:5409-5415.
39. Sala-Newby GB, Skladanowski AC, Newby AC. The mechanism of adenosine formation in cells. Cloning of cytosolic 5′-nucleotidase-1. J Biol Chem. 1999;274:17789-17793.
40. Rampazzo C, Gallinaro L, Milanesi E, Frigimelica E, Reichard P, Bianchi V. A deoxyribonucleotidase in mitochondria: involvement in regulation of dNTP pools and possible link to genetic disease. Proc Natl Acad Sci U S A. 2000;97:8239-8244.
41. Pieters R, Veerman AJ. The role of 5′nucleotidase in therapy-resistance of childhood leukemia. Med Hypotheses. 1988;27:77-80.
42. Veerman AJ, Hogeman PH, van Zantwijk CH, Bezemer PD. Prognostic value of 5′nucleotidase in acute lymphoblastic leukemia with the common-ALL phenotype. Leuk Res. 1985;9:1227-1229.
43. Pieters R, Huismans DR, Loonen AH, et al. Relation of 5′-nucleotidase and phosphatase activities with immunophenotype, drug resistance and clinical prognosis in childhood leukemia. Leuk Res. 1992;16:873-880.
44. Kawasaki H, Carrera CJ, Piro LD, Saven A, Kipps TJ, Carson DA. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood. 1993;81:597-601.
45. Arner ES. On the phosphorylation of 2-chlorodeoxyadenosine (CdA) and its correlation with clinical response in leukemia treatment. Leuk Lymphoma. 1996;21:225-231.